Analysts Changed Price Targets on These Stocks Today - Wall St. Cheat Sheet
Fri, 15 Jul 2011 14:55The Company develops therapeutics that modulate the immune response through Toll-like receptors. Idera is working on therapeutics for oncology, asthma/allergy, and infectious diseases. (Note: Data on stock ratings is sourced from here. ...
XOMA Discovers Two New Classes of Insulin Receptor-Regulating Antibodies - Gamut News (press release)
Mon, 27 Jun 2011 12:04XOMA 3AB is in a Phase 1 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The XOMA 3AB project has been funded in whole or in part with funds from NIAID, NIH, ...
Baines: Would-be pharmaceutical companies give shareholders headaches - Vancouver Sun
Wed, 29 Jun 2011 14:26The stock cruised along at the $2.50 level for most of 2010, but to date, the company hasn't generated a cent of revenue, and the share price has slumped to 19 cents. Meanwhile, in March 2010, Salari acquired control of a shell company whose shares ...
Sector:
